Complement component C5 is the target of the monoclonal antibody Eculizumab, and the focus of a sustained drug discovery effort to prevent complement-induced inflammation in a range of autoimmune diseases. The immune evasion...
Complement component C5 is the target of the monoclonal antibody Eculizumab, and the focus of a sustained drug discovery effort to prevent complement-induced inflammation in a range of autoimmune diseases. The immune evasion...
In this work we present a number of urn models in which, contrary to standard Pólya urns, the number of competing alternatives is not given from the outset but may increase with the arrival of innovations. We begin by...
|< |
< |
1 |